Inovio Pharmaceuticals (NASDAQ:INO) Given Market Outperform Rating at JMP Securities

JMP Securities restated their market outperform rating on shares of Inovio Pharmaceuticals (NASDAQ:INO) in a report released on Friday,Benzinga reports. JMP Securities currently has a $18.00 price target on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the company. Royal Bank of Canada reduced their price objective on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Friday, November 15th. HC Wainwright decreased their price target on shares of Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating for the company in a report on Monday, November 18th. Finally, Oppenheimer dropped their price objective on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research note on Monday, November 18th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Inovio Pharmaceuticals has a consensus rating of “Hold” and an average price target of $12.80.

Inovio Pharmaceuticals Stock Down 5.3 %

Shares of INO stock opened at $1.98 on Friday. Inovio Pharmaceuticals has a one year low of $1.74 and a one year high of $14.75. The company’s 50-day simple moving average is $3.49 and its 200-day simple moving average is $6.15.

Institutional Trading of Inovio Pharmaceuticals

Several hedge funds have recently bought and sold shares of INO. BNP Paribas Financial Markets grew its stake in shares of Inovio Pharmaceuticals by 177.0% in the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 3,630 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in Inovio Pharmaceuticals during the 2nd quarter valued at about $82,000. SG Americas Securities LLC bought a new stake in shares of Inovio Pharmaceuticals during the 3rd quarter worth about $71,000. MetLife Investment Management LLC lifted its stake in shares of Inovio Pharmaceuticals by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 8,546 shares during the period. Finally, Atom Investors LP bought a new position in shares of Inovio Pharmaceuticals in the third quarter valued at approximately $103,000. 26.79% of the stock is currently owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.